Healthcare / BiotechnologyTaipei Exchange
$26.05
+0.10 (+0.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-99.6M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.4%
↓Gross Margin
72.0%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+91.9%
FCF CAGR
—
FCF margin
-29.5%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $222.3M · net income $-84.6M · FCF $-65.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $222.3M | $222.3M | $167.6M | $109.9M | $31.4M |
| Net Income | $-84.6M | $-84.6M | $-116.5M | $-156.3M | $-184.5M |
| EBITDA | $-53.7M | $-53.7M | $-76.8M | $-113.9M | $-160.6M |
| EPS | — | — | -0.95 | -1.30 | -1.78 |
| Gross Margin | 72.0% | 72.0% | 77.8% | 81.5% | 72.4% |
| Operating Margin | -49.3% | -49.3% | -72.9% | -160.6% | -697.1% |
| Net Margin | -38.1% | -38.1% | -69.5% | -142.2% | -586.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 34.37 | 34.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-65.5M | $-65.5M | $-99.6M | $-164.4M | $-187.0M |
| Returns | |||||
| ROE | -11.4% | -11.4% | -14.2% | -16.6% | -26.2% |
| Valuation | |||||
| P/B | 4.38 | 4.38 | 5.00 | 4.90 | 3.14 |
| Growth & Yield | |||||
| Revenue Growth | 32.6% | 32.6% | 52.5% | 249.5% | — |
| EPS Growth | — | — | 26.9% | 27.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.95 → n/d
Residual
-7.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.